Genentech Says IP Suit Should End After Phigenix Attys Leave
Genentech Inc. told a California federal judge Thursday that it will move to end Phigenix Inc.'s patent infringement suit over a breast cancer drug after the judge allowed Phigenix's attorneys to...To view the full article, register now.
Already a subscriber? Click here to view full article